Smooth muscle cell pathophysiology and advanced glycation end products (AGEs)

Current Drug Targets

Volumn 11, Issue 7, 2010, Pages 875-881

  Yamagishi, Sho ichi ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Cardiovascular disease; Oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALGRANULIN A; CALGRANULIN B; CHYMASE; GELATINASE A; GELATINASE B; GLUCOSE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCALCIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN INTERACTING WITH PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DRUG DELIVERY SYSTEMS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, CARDIOVASCULAR; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, IMMUNOLOGIC;

EID: 77954716681     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791320827     Document Type: Article

References (69)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
3. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The diabetes control and complications trial/epidemiology of diabetes interventions and complications research group. N Engl J Med 2000; 342: 381-9.
5. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The epidemiology of diabetes interventions and complications (edic) study. JAMA 2003; 290: 2159-67.
6. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-303.
7. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
9. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-34.
10. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654-60.
11. Grandhee SK, Monnier VM. Mechanism of formation of the maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991; 266: 11649-53.
12. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79.
13. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
14. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. Ages and their interaction with age-receptors in vascular disease and diabetes mellitus. I. The age concept. Cardiovasc Res 1998; 37: 586-600.
15. Schmidt AM, Stern D. Atherosclerosis and diabetes: The rage connection. Curr Atheroscler Rep 2000; 2: 430-6.
16. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (srage) in diabetes. Curr Drug Targets 2007; 8: 1138-43.
17. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (ages) in the pathogenesis of alzheimer's disease. Curr Pharm Des 2008; 14: 973-8.
18. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the maillard reaction. J Biol Chem 1995; 270: 10017-26.
19. Bucala R, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
20. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51.
21. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: Promotion, progression, and prevention. Ann N Y Acad Sci 1997; 811: 115-27.
22. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. Tage (toxic ages) theory in diabetic complications. Curr Mol Med 2006; 6: 351-8.
23. Yoon SJ, Yoon YW, Lee BK, et al. Potential role of hmg coa reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009; 41: 802-11.
24. Yoon YW, Kang TS, Lee BK, et al. Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy. Exp Mol Med 2008; 40: 398-406.
25. San Martin A, Foncea R, Laurindo FR, Ebensperger R, Griendling KK, Leighton F. Nox1-based nadph oxidase-derived superoxide is required for vsmc activation by advanced glycation end-products. Free Radic Biol Med 2007; 42: 1671-9.
26. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-4.
27. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30.
28. Okamoto T, Yamagishi S, Inagaki Y, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 2002; 297: 419-24.
29. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20.
30. Wu S, Song T, Zhou S, et al. Involvement of na+/h+ exchanger 1 in advanced glycation end products-induced proliferation of vascular smooth muscle cell. Biochem Biophys Res Commun 2008; 375: 384-9.
31. David KC, Scott RH, Nixon GF. Advanced glycation endproducts induce a proliferative response in vascular smooth muscle cells via altered calcium signaling. Biochem Pharmacol 2008; 76: 1110-20.
32. Seki N, Hashimoto N, Taira M, et al. Regulation of src homology 2-containing protein tyrosine phosphatase by advanced glycation end products: The role on atherosclerosis in diabetes. Metabolism 2007; 56: 1591-8.
33. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009; 37: 847-54.
34. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through rage/p38 mapk. J Vasc Res 2009; 46: 572-80.
35. Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 1999; 258: 353-7.
36. Higashi T, Sano H, Saishoji T, et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 1997; 46: 463-72.
37. Thallas-Bonke V, Lindschau C, Rizkalla B, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker alt-711 via a protein kinase c-alpha-dependent pathway. Diabetes 2004; 53: 2921-30.
38. Iino K, Yoshinari M, Yamamoto M, et al. Effect of glycated collagen on proliferation of human smooth muscle cells in vitro. Diabetologia 1996; 39: 800-6.
39. Sakata N, Sasatomi Y, Meng J, et al. Possible involvement of altered rgd sequence in reduced adhesive and spreading activities of advanced glycation end product-modified fibronectin to vascular smooth muscle cells. Connect Tissue Res 2000; 41: 213-28.
40. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM. Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-i collagen matrix. Int J Biochem Cell Biol 2004; 36: 840-8.
41. Bobbink IW, de Boer HC, Tekelenburg WL, Banga JD, de Groot PG. Effect of extracellular matrix glycation on endothelial cell adhesion and spreading: Involvement of vitronectin. Diabetes 1997; 46: 87-93.
42. Kalfa TA, Gerritsen ME, Carlson EC, Binstock AJ, Tsilibary EC. Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Vis Sci 1995; 36: 2358-67.
43. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits ages-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000; 274: 61-7.
44. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000; 7: 169-76.
45. Sakaguchi T, Yan SF, Yan SD, et al. Central role of rage-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-72.
46. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-56.
47. Inoue K, Kawahara K, Biswas KK, et al. Hmgb1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007; 16: 136-43.
48. Cipollone F, Iezzi A, Fazia M, et al. The receptor rage as a progression factor amplifying arachidonate-dependent inflamma-tory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003; 108: 1070-7.
49. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (ages): A novel therapeutic target for various disorders. Curr Pharm Des 2007; 13: 2832-6.
50. Silverstein RL. Inflammation, atherosclerosis, and arterial thrombosis: Role of the scavenger receptor cd36. Cleve Clin J Med 2009; 76(Suppl 2): S27-30.
51. Sima AV, Botez GM, Stancu CS, Manea A, Raicu M, Simionescu M. Effect of irreversibly glycated ldl in human vascular smooth muscle cells: Lipid loading, oxidative and inflammatory stress. J Cell Mol Med 2009 (in press).
52. Ohgami N, Nagai R, Ikemoto M, et al. Cd36, a member of class b scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2001; 947: 350-5.
53. de Oliveira Silva C, Delbosc S, Arais C, Monnier L, Cristol JP, Pares-Herbute N. Modulation of cd36 protein expression by ages and insulin in aortic vsmcs from diabetic and non-diabetic rats. Nutr Metab Cardiovasc Dis 2008; 18: 23-30.
54. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17: 23S-30S.
55. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin ii type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (ppar-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-9.
56. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (age)-receptor (rage) system by ppar-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009; 60: 174-8.
57. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-8.
58. Wang K, Zhou Z, Zhang M, et al. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 2006; 317: 37-43.
59. De Oliveira C, Colette C, Monnier L, Descomps B, Pares-Herbute N. Insulin alters nuclear factor-lambdab and peroxisome proliferator-activated receptor-gamma protein expression induced by glycated bovine serum albumin in vascular smooth-muscle cells. J Lab Clin Med 2005; 145: 144-50.
60. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB. S100b-rage-mediated augmentation of angiotensin ii-induced activation of jak2 in vascular smooth muscle cells is dependent on pld2. Diabetes 2003; 52: 2381-8.
61. Ihara Y, Egashira K, Nakano K, et al. Upregulation of the ligand-rage pathway via the angiotensin ii type i receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiol 2007; 43: 455-64.
62. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. Angiotensin ii augments advanced glycation end product-induced pericyte apoptosis through rage overexpression. FEBS Lett 2005; 579: 4265-70.
63. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin ii-generating pathway in diabetic complications. Circulation 2006; 113: 1353-60.
64. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-31.
65. Bucciarelli LG, Wendt T, Qu W, et al. Rage blockade stabilizes established atherosclerosis in diabetic apolipoprotein e-null mice. Circulation 2002; 106: 2827-35.
66. Li XL, Li BY, Gao HQ, et al. Effects of grape seed proantho-cyanidin extracts on aortic pulse wave velocity in streptozocin induced diabetic rats. Biosci Biotechnol Biochem 2009; 73: 1348-54.
67. Ouyang P, Peng LS, Yang H, Peng WL, Wu WY, Xu AL. Recombinant human interleukin-10 inhibits proliferation of vascular smooth muscle cells stimulated by advanced glycation end products and neointima hyperplasia after carotid injury in the rat. Sheng Li Xue Bao 2003; 55: 128-34.
68. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
69. Uk prospective diabetes study (ukpds) group. Intensive blood-conventional treatment and risk of complications in patients with glucose control with sulphonylureas or insulin compared with type 2 diabetes (ukpds 33). Lancet 1998; 352: 837-53.